Benzinga's Volume Movers

shares climbed 43.80 percent to $23.56. The volume of Sarepta Therapeutics shares traded was 1848 percent higher than normal. Sarepta Therapeutics surged following the announcement of submission of rolling NDA for Eteplirsen. SunTrust Robinson Humphrey upgraded Sarepta Therapeutics from Neutral to Buy and raised the price target from $14.00 to $33.00.

surged 10.42 percent to $11.76. The volume of Genocea Biosciences shares traded 1254 percent higher than normal. Genocea Biosciences reported positive top-line data from its Phase 2 dose optimization trial of GEN-003.

shares moved up 3 percent to $28.12. The volume of Engility Holdings traded was 623 percent higher than normal. Engility has been awarded a $10.5 million contract to support U.S. Army's logistics modernization program.

shares rose 19.17 percent to $54.90. The volume of Dycom Industries shares traded was 484 percent higher than normal. Dycom reported stronger-than-expected Q3 results and issued an upbeat forecast.